COX-2 inhibition and prevention of cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Cyclo-oxygenase (COX) inhibition is explored for cancer prevention and treatment, based on epidemiological and experimental evidence.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin show potential but have significant gastrointestinal toxicity.
• Increased COX-2 expression is observed in many common cancers, suggesting it as a therapeutic target.

Purpose of the Study:

• To evaluate the antineoplastic potential of COX-2 inhibitors in cancer prevention and treatment.
• To explore the therapeutic possibilities offered by selective COX-2 inhibitors.
• To investigate novel mechanisms of action for COX-2 inhibitors beyond cyclo-oxygenase inhibition.

Main Methods:

• Review of epidemiological data on NSAID use and cancer incidence.
• Analysis of animal experiments and molecular genetics studies.
• Clinical trials evaluating NSAIDs and selective COX-2 inhibitors in cancer patients and prevention studies.

Main Results:

• NSAIDs, including sulindac, have shown efficacy in reducing polyps in familial adenomatous polyposis.
• Selective COX-2 inhibitors offer therapeutic potential with reduced gastrointestinal side effects compared to traditional NSAIDs.
• A non-COX-2 mechanism involving PPARdelta and APC tumor suppressor activity has been identified for COX-2 inhibitors.

Conclusions:

• Selective COX-2 inhibitors represent a promising therapeutic strategy for cancer prevention and treatment.
• Celecoxib is approved for familial adenomatous polyposis, with ongoing trials for other cancers like colorectal, prostate, and breast cancer.
• Further research is warranted to fully elucidate the antineoplastic mechanisms and clinical applications of COX-2 inhibitors.